Goldman Sachs Group Inc Catalyst Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,411,660 shares of CPRX stock, worth $49.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,411,660
Previous 3,135,473
23.08%
Holding current value
$49.5 Million
Previous $76 Million
31.17%
% of portfolio
0.01%
Previous 0.01%
Shares
22 transactions
Others Institutions Holding CPRX
# of Institutions
386Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$384 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$180 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$112 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$66.8 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$65.4 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.11B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...